INVESTOR ALERT: RGRD Law Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead the Procept Class Action Lawsuit - PRCT

Robbins Geller Rudman & Dowd LLP announces that purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, both dates inclusive (the “Class Period”), have until September 22, 2026 to seek appointment as lead plaintiff of the Procept class action lawsuit.

The Procept class action lawsuit alleges that defendants throughout the Class Period made materially false and/or misleading statements because they failed to disclose the following adverse facts pertaining to Procept’s business, operations, and financial condition, which were known to defendants or recklessly disregarded by them as follows: (i) that, during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated Procept’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of (i)-(iv) above, defendants’ representations during the Class Period regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of (i)-(v) above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of (i)-(vi) above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.

The Procept class action lawsuit further alleges that on August 6, 2025, Procept announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter. During Procept’s earnings call, defendant Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates of more than 13,840 units. Procept’s quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in or...